Novo Nordisk's Wegovy indtager markedet og aktierne stiger - læs om de seneste resultater!
Novo Nordisk har netop lagt kvartalsresultaterne på bordet, og det er ingen overraskelse, at interessen for deres vægttabsmedicin, Wegovy, fortsætter med at eksplodere! I den seneste rapport kunne de præsentere en stigning i salget, der oversteg forventningerne, hvilket giver både investorer og diætister noget at smile over. CEO Lars Fruergaard Jørgensen har med sin styring af virksomheden ikke kun skabt tryghed blandt aktionærerne, men også sørget for netop den optimale opskrift for succes - basta med de kedelige kostplaner!
Men lad os ikke glemme puden af omsætning fra Ozempic, Novo Nordisks diabetesmedicin, som desværre ikke levede op til forventningerne. Denne lille skuffelse fik aktierne til at dippe en smule. På den positive side, er det altid godt at vide, at Wegovy igen imponerede med sin populære internationale udrulning, og at det dermed er ved at blive en global succes, som flere og flere har fået øjnene op for. Hvad med dig? Overvejer du også at få en portion Wegovy i din hverdag?
Novo Nordisk fastholder også en stærk fremadskuende prognose med et fornyet fokus på deres kræftmedicin og andre innovative behandlingsmuligheder. Det betyder, at de ikke bare sidder stille og ser på, men aktivt udforsker flere muligheder for vækst. Det er en spændende tid for virksomheden, der ser ud til at have kurven med vægtab og sundhed i højsædet.
Men vidste du, at Wegovy har vist sig at være mere end blot en kur for overvægt? Forskning viser, at det også kan have positive effekter på hjertesundhed. Dette er især gode nyheder for dem, der kæmper med både vægt og kardiovaskulære problemer. Og med Novo Nordisks fortsatte fokus på forskning og udvikling vil vi sandsynligvis se endnu flere innovative løsninger i fremtiden!
Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker ...
Novo Nordisk CEO Lars Fruergaard Jorgensen has led the company to record fortunes. Al Drago/Bloomberg via Getty Images. Novo Nordisk A/ ...
Novo Nordisk stock rises after weight-loss drug sales were mixed. Ozempic sales miss expectations and Wegovy sales beat estimates in the third quarter.
Novo Nordisk's U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including ...
LONDON — Sales of Novo Nordisk's obesity drug Wegovy jumped in the third quarter, the company said Wednesday as it reported quarterly profits that were in ...
Maker of blockbuster Wegovy and Ozempic treatments reports 21% rise in third-quarter sales.
By Steve Goldstein. Novo Nordisk on Wednesday nudged higher its profit outlook for the year as the drugmaker registered another quarter of strong sales of ...
Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.
Novo Nordisk (NVO) stock dipped early Wednesday on mixed third-quarter results as sales of weight-loss drug Wegovy beat expectations, but Ozempic came in ...
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive ...
The Danish pharma bought the nonsteroidal mineralocorticoid receptor antagonist, called ocedurenone, from KBP Biosciences a year ago. The thinking was that the ...
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...
Sales of the GLP-1RA hit $2.5bn in Q3, a 79% increase over the same period last year.
My name is Jacob Martin Wiborg Rode, and I'm the head of investor relations at Novo Nordisk. With me today, I have CEO of Novo Nordisk, Lars Fruergaard ...
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 ...
Novo Nordisk will terminate development of ocedurenone for treatment of hypertension in chronic kidney disease (CKD).